40481-13-8

Basic information

• Product Name: 4-PHENYL-PIPERIDINE-4-CARBONITRILE
• Synonyms: 4-PHENYL-PIPERIDINE-4-CARBONITRILE;4-Phenyl-4-piperidinecarbonitrile
• CAS NO: 40481-13-8
• Molecular Formula: C₁₂H₁₄N₂
• Molecular Weight: 186.25
• Mol File: 40481-13-8.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 145-146 °C(Press: 2 Torr)
• Appearance: /
• Density: 1.08±0.1 g/cm3(Predicted)
• PKA: 9.01±0.10(Predicted)
• CAS DataBase Reference: 4-PHENYL-PIPERIDINE-4-CARBONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-PHENYL-PIPERIDINE-4-CARBONITRILE(40481-13-8)
• EPA Substance Registry System: 4-PHENYL-PIPERIDINE-4-CARBONITRILE(40481-13-8)

Safety Data

• Hazardous Substances Data: 40481-13-8(Hazardous Substances Data)

Usage

General Description

4-Phenyl-piperidine-4-carbonitrile is a chemical compound with the molecular formula C15H15N3. It is a white to off-white powder that is soluble in organic solvents. 4-PHENYL-PIPERIDINE-4-CARBONITRILE is commonly used as a building block for the synthesis of various pharmaceutical and organic compounds. It has been studied for its potential use in the development of new medications, particularly for its potential as an antipsychotic drug. The compound's structure consists of a piperidine ring with a phenyl group and a carbonitrile group attached, making it a versatile intermediate in organic synthesis. It is important to handle and utilize 4-phenyl-piperidine-4-carbonitrile with proper safety precautions, as it can be hazardous if not handled properly.

Upstream product

• 140-29-4 phenylacetonitrile 
• 334-22-5 N,N-bis(chloro-2-ethyl)amine 
• 51304-58-6 4-cyano-4-phenylpiperidine hydrochloride 
• 71258-18-9 1-benzyl-4-phenyl-piperidine-4-carbonitrile; hydrochloride 
• 56243-25-5 1-benzyl-4-cyano-4-phenylpiperidine 
• 158144-79-7 tert-butyl 4-cyano-4-phenylpiperidine-1-carboxylate 

Downstream Products

• 761355-17-3 (4-phenylpiperidin-4-yl)methanamine 
• 158144-79-7 tert-butyl 4-cyano-4-phenylpiperidine-1-carboxylate 
• 538324-25-3 1-cyclopentyl-4-phenyl-piperidine-4-carbonitrile 
• 1041870-85-2 4-phenyl-1-(3-phenyl-propyl)-piperidine-4-carbonitrile 
• 42520-99-0 1-butyl-4-phenyl-piperidine-4-carbonitrile 
• 1041870-79-4 4-phenyl-1-propyl-piperidine-4-carbonitrile 
• 159634-80-7 1,2,3,4-tetrahydrospiro[isoquinolin-4,4'-piperidine]-1'-carboxylic acid, 1,1-dimethylethyl ester 
• 906369-80-0 4-[(2-nitro-benzenesulfonylamino)-methyl]-4-phenyl-piperidine-1-carboxylic acid tert-butyl ester 
• 906369-83-3 C₂₄H₂₉N₃O₆S 
• 158144-82-2 tert. butyl 4-aminomethyl-4-phenyl-piperidine-1-carboxylate 
• 199104-96-6 4-(Methanesulfonylamino-methyl)-4-phenyl-piperidine-1-carboxylic acid tert-butyl ester 
• 1254948-89-4 C₁₈H₁₅F₆N₃OS 

Relevant articles and documents

Muscarinic acetylcholine receptor binding affinities of pethidine analogs

A series of pethidine analogs were synthesized and their affinities for the [3H]N-methyl-scopolamine (NMS) binding site on muscarinic acetylcholine receptors (mAChRs) were determined using M1, M3 or M5 human mAChRs expressed by Chinese hamster ovary (CHO) cell membranes. Compound 6b showed the highest binding affinities at M1, M3 and M5 mAChRs (Ki = 0.67, 0.37, and 0.38 μM, respectively).

DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS

The present invention relates to new drug combinations which contain in addition to one or more PDE4-inhibitors at least one NSAID (=non-steroidal anti-inflammatory drug) (2), processes for preparing them and their use in treating in particular respiratory complaints such as for example COPD, chronic sinusitis and asthma. The invention particularly relates to those drug combinations which contain, in addition to one or more, preferably one PDE4 inhibitor of general formula 1 wherein X is SO or SO2, but preferably SO, and wherein R1, R2, R3 and R4 have the meanings given in claim 1, at least one NSAID (2), the preparation thereof and the use thereof for the treatment of respiratory complaints.

METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.